Clinical trial
A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib
NCT01900652 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2013
- Completion date
- March 31, 2016
- Enrollment
- 111 (actual)
- Sites
- 59
Conditions
As the registry lists them; a condition with its own page is linked.